The deal is the second acquisition for CG Life this year, following the addition of Toolhouse in March.
The Proteologix deal marks the second big pharma buy for J&J in 2024, following its acquisition of Amrbx Biopharma earlier this year.
Following a downturn in M&A activity during 2022 and 2023, the biopharma industry is increasing its level of dealmaking.
Quinn will oversee the region as Americas president in digital agency’s latest restructure.
Area 23 will absorb McCann Health New York, while Hill Holliday Health and McCann Health New Jersey will merge under the new Rise & Run brand.
Speculation has created what one insider calls a ‘febrile’ atmosphere at the top of the agency sector.
The $2.4 billion deal will bring Deciphera’s cancer drugs Qinlock, vimseltinib and DCC-3116 under Ono Pharmaceutical’s umbrella.
The deal took place as BCW is combining with Hill & Knowlton to form Burson.
The acquisition will give Incyte two dermatology drugs currently being investigated for several inflammatory skin diseases.
The firms have ‘identified areas in the business where we must eliminate roles, many of which were duplicate,’ staffers were told in a memo.
Get the most out of
Register for free and enjoy unlimited access to: